These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Exempt 2016-000286-23 Phase I/II, First in Human, Dose Escalation Trial of TL-895 in Subjects with Relapsed/Refractory B-Cell Malignancies and Expansion in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia or ... not-yet-due
Exempt, with results Terminated 2020-002259-39 A Phase 1/2, Double-Blind, Randomized, Placebo-Controlled Study of TL-895 with Standard Available Treatment versus Standard Available Treatment for the Treatment of COVID-19 in Patients with Cancer 2021-01-15 not-yet-due
Ongoing 2020-002393-27 A Phase 2, Multicenter Study of TL-895 in Subjects with Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis, Janus Kinase Inhibitor Treatment Ineligible Myelofibrosis, o... not-yet-due
Exempt 2020-003109-73 An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined with KRT-232 in Subjects with Relapsed/Refractory (R/R) FLT3+ Acute Myeloid Leukemia (AML) 2023-02-19 not-yet-due
Exempt 2021-005724-38 An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined with Ruxolitinib in Janus associated Kinase Inhibitor (JAKi) Treatment-Naïve Myelofibrosis (MF) Subjects and ... 2023-07-18 not-yet-due